论文部分内容阅读
目的研究分析格列美服联合阿卡波糖治疗新诊断2型糖尿病的临床效果。方法 100例新诊断2型糖尿病患者,随机分为对照组与研究组,各50例。对照组采用格列美服进行治疗,研究组在对照组基础上联合阿卡波糖进行治疗,比较两组治疗效果。结果两组治疗后总有效率进行比较,研究组明显高于对照组,差异具有统计学意义(P<0.05);研究组血糖控制情况优于对照组,差异具有统计学意义(P<0.05);两组患者不良反应发生情况比较,差异无统计学意义(P>0.05)。结论采用格列美服联合阿卡波糖治疗新诊断2型糖尿病临床效果显著,可以稳定控制血糖,不良反应少,安全性高,值得临床广泛推广应用。
Objective To study the clinical efficacy of glimepiride combined with acarbose in the treatment of newly diagnosed type 2 diabetes mellitus. Methods One hundred cases of newly diagnosed type 2 diabetic patients were randomly divided into control group and study group, 50 cases each. The control group was treated with glimepiride. The study group was treated with acarbose on the basis of the control group, and the treatment effect was compared between the two groups. Results The total effective rate of the two groups after treatment were compared, the study group was significantly higher than the control group, the difference was statistically significant (P <0.05); the study group blood glucose control situation is better than the control group, the difference was statistically significant (P <0.05) There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusion The combination of gliclazide and acarbose in the treatment of newly diagnosed type 2 diabetes has remarkable clinical effect, stable blood sugar control, few side effects and high safety. It is worth widely clinical application.